NIMER STEPHEN 4

Accession 0001181431-10-051417

CIK 0001409012other

View on SEC.gov Company Profile

Filed

Oct 18, 8:00 PM ET

Accepted

Oct 19, 5:39 PM ET

Size

26.3 KB

Accession

0001181431-10-051417

Insider Transaction Report

Form 4

Period: 2010-10-15

Abraxis BioScience, Inc.ABII

NIMER STEPHEN

Director

Transactions

Disposition to Issuer
Non-qualified Stock Option
2010-10-15$35.06/sh−10,000$350,600→ 0 total
Exercise: $38.08From: 2010-12-10Exp: 2019-12-10→ Common Stock (10,000 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15−2,970→ 0 total
Exercise: $94.84From: 2007-11-29Exp: 2015-07-21→ Common Stock (2,970 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$66.85/sh−4,773$319,075→ 0 total
Exercise: $6.29From: 2007-11-29Exp: 2011-07-16→ Common Stock (4,773 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$38.49/sh−1,909$73,477→ 0 total
Exercise: $34.65From: 2007-11-29Exp: 2013-04-24→ Common Stock (1,909 underlying)
Disposition to Issuer
Common Stock
2010-10-15−1,875→ 0 total
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$43.70/sh−1,909$83,423→ 0 total
Exercise: $29.44From: 2007-11-29Exp: 2012-10-25→ Common Stock (1,909 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15−1,272→ 0 total
Exercise: $95.26From: 2007-11-29Exp: 2015-06-17→ Common Stock (1,272 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$25.84/sh−4,243$109,639→ 0 total
Exercise: $47.30From: 2007-11-29Exp: 2016-08-01→ Common Stock (4,243 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$47.99/sh−4,773$229,056→ 0 total
Exercise: $25.15From: 2007-11-29Exp: 2010-12-14→ Common Stock (4,773 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15−1,272→ 0 total
Exercise: $82.94From: 2007-11-29Exp: 2014-12-13→ Common Stock (1,272 underlying)
Disposition to Issuer
Non-qualified Stock Option
2010-10-15$17.70/sh−10,000$177,000→ 0 total
Exercise: $55.44From: 2007-11-29Exp: 2017-11-29→ Common Stock (10,000 underlying)

Footnotes (2)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of June 30, 2010 ("Merger Agreement"), among Celgene Corporation ("Celgene"), Artistry Acquisition Corp. ("Merger Sub") and Abraxis BioScience, Inc. ("Abraxis"), whereby Merger Sub merged into Abraxis, with Abraxis continuing as the surviving company and a wholly owned subsidiary of Celgene (the "Merger"), each share was converted into the right to receive (i) an amount in cash equal to $58.00, (ii) 0.2617 of a share of Celgene common stock and (iii) a contingent value right issued by Celgene.
[F2]Pursuant to the Merger Agreement, this option was cancelled at the effective time of the Merger in exchange for (i) a cash payment equal to the excess of $73.14 per share over the exercise price per share of this option and (ii) a contingent value right issued by Celgene.

Documents

1 file

4
rrd288879.xmlPrimary
FORM 4

Issuer

Abraxis BioScience, Inc.

CIK 0001409012

→

Entity typeother

Related Parties

filerCIK 0001189023

Filing Metadata

Form type: 4
Filed: Oct 18, 8:00 PM ET
Accepted: Oct 19, 5:39 PM ET
Size: 26.3 KB

View on SEC.gov